1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Evotec Spin-Off Eyes Early Clinical POC With Immune Tolerance Platform

 
• By Sukaina Virji

Evotec AG of Germany has spun out a drug discovery company called Topas Therapeutics GmbH. It is being launched with a €14m series A financing round led by VC firm Epidarex Capital, of which Eli Lilly is an investor. The round also included EMBL Ventures, Gimv and Evotec.

Evotec AG of Germany has spun out a drug discovery company called Topas Therapeutics GmbH. It is being launched with a €14m series A financing round led by VC firm Epidarex Capital, of which Eli Lilly is an investor. The round also included EMBL Ventures, Gimv and Evotec.

Topas has been built around technology licensed from the University Medical Center Hamburg-Eppendorf where it was invented by Dr Johannes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

More from Therapy Areas

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.